Synlogic secures $30M to develop bacteria designed to treat specific diseases

07/22/2014 | Xconomy

Synlogic, a startup company based in Cambridge, Mass., has won a $29.4 million Series A grant from Atlas Venture and New Enterprise Associates. The firm plans to develop genetically manipulated microbes that can sense or identify diseases, counter or treat the disease by secreting a drug or antimicrobial peptide, and then self-destruct once its task is complete. The funding will be given to the company in portions and is contingent on the progress of the project.

View Full Article in:

Xconomy

Published in Brief: